Cart
sales@molnova.com
Mevociclib
CAS No. 1816989-16-8
Mevociclib( SY-1365 )
Catalog No. M26471 CAS No. 1816989-16-8
Mevociclib is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 262 | Get Quote |
|
| 50MG | 1485 | Get Quote |
|
| 100MG | 2520 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameMevociclib
-
NoteResearch use only, not for human use.
-
Brief DescriptionMevociclib is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.
-
DescriptionMevociclib is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.
-
In Vitro——
-
In VivoAnimal Model:Mice, HCC70 xenograft model Dosage:20 mg/kg Administration:Intravenous injection, twice weekly, for 35 days Result:Inhibited tumor volume in vivo.
-
SynonymsSY-1365
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorAkt| caspase-3| JNK1| p44/42 MAPK| RhoGDI
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1816989-16-8
-
Formula Weight587.13
-
Molecular FormulaC31H35ClN8O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (212.90 mM)
-
SMILESCN(C)C\C=C\C(=O)Nc1ccc(nc1)C(=O)N[C@@]1(C)CCC[C@H](C1)Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kohno K, Ohashi E, et al. Anti-inflammatory effects of adenosine N1-oxide. J Inflamm (Lond). 2015 Jan 20;12(1):2.
molnova catalog
related products
-
JH-VIII-49
JH-VIII-49 is a potent and selective inhibitor of CDK8 with IC50 of 16 nM, also inhibits CDK19 (IC50=8 nM).
-
Pinoresinol
Pinoresinol has antiinflammatory, hepatoprotective, and fungicidal activities, it can protect pial microcirculation from I-reperfusion injury, to increase nitric oxide release and to reduce oxidative stress preserving pial blood flow distribution.
-
CCT-251921
A potent, selective, and orally bioavailable inhibitor of CDK8 and CDK19 with IC50of 2.3 nM and 2.6 nM respectively.
